Rockwell Medical (RMTI) Expected to Announce Earnings on Thursday

Rockwell Medical (NASDAQ:RMTI) is expected to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $17.9540 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Rockwell Medical (NASDAQ:RMTI) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.05). Rockwell Medical had a negative net margin of 7.67% and a negative return on equity of 15.64%. The business had revenue of $18.35 million during the quarter, compared to analysts’ expectations of $18.58 million. On average, analysts expect Rockwell Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Rockwell Medical Stock Up 0.1%

Shares of NASDAQ RMTI traded up $0.00 during midday trading on Tuesday, hitting $0.89. The company’s stock had a trading volume of 39,836 shares, compared to its average volume of 564,667. The business’s fifty day simple moving average is $0.93 and its two-hundred day simple moving average is $0.97. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.63. Rockwell Medical has a 1 year low of $0.78 and a 1 year high of $2.10. The firm has a market capitalization of $35.11 million, a price-to-earnings ratio of -5.93 and a beta of 1.65.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RMTI. Vanguard Group Inc. lifted its stake in Rockwell Medical by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after acquiring an additional 148,737 shares during the last quarter. Geode Capital Management LLC lifted its stake in Rockwell Medical by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after acquiring an additional 41,668 shares during the last quarter. Jane Street Group LLC purchased a new position in Rockwell Medical in the fourth quarter worth approximately $84,000. Finally, XTX Topco Ltd raised its holdings in Rockwell Medical by 286.5% during the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after purchasing an additional 46,029 shares in the last quarter. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on RMTI shares. Wall Street Zen raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rockwell Medical in a research note on Tuesday, April 21st. Finally, HC Wainwright decreased their price target on shares of Rockwell Medical from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Monday, March 30th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $2.00.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.